Company intelligence / Profile preview
Baliopharm AG
Reinach, Basel-Landschaft, Switzerlandbaliopharm.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Baliopharm AG develops innovative monoclonal antibody therapeutics targeting chronic liver diseases like NASH, autoimmune disorders such as rheumatoid arthritis and Crohn’s disease, and cancer. Its lead candidate ATROSIMAB completed a successful Phase I trial in NASH with no serious side effects reported. The company aims to advance its programs through early clinical stages before seeking partnerships for later-stage development or commercialization.[2][3][4]
- Therapeutic areas
- GastroenterologyOncologyImmunologyDermatology
- Modalities
- Monoclonal antibodies (mAbs)Antibody-derived therapeuticsBiosimilars
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Outlicensing partnership with Xlife Sciences AG for ATROSIMAB; intent to partner after phase II proof-of-concept for other compounds.[3][4]
Beyond the preview
Go deeper on Baliopharm AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Baliopharm AG.